secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tempest Therapeutics, Inc. (TPST)
CIK:        0001544227
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0000950170-24-094102
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tempest reports Q2 2024 financials; amezalpat shows 6-month survival benefit in liver cancer study
--------------------------------------------------------------------------------

- Amezalpat median OS 21 months vs 15 months control (6-month improvement); HR 0.65 stable from prior 0.59.
- Company plans to advance amezalpat into a registrational Phase 3 study in first-line HCC.
- TPST-1495 to enter Phase 2 in Familial Adenomatous Polyposis in 2024 under NCI funding.
- Q2 2024 net loss $9.6M ($0.42 per share); cash and equivalents $31.1M as of June 30, 2024.
- R&D expenses $5.8M in Q2 2024 vs $4.4M in Q2 2023, increase due to CRO costs and stock compensation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1544227/000095017024094102/0000950170-24-094102-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1544227/000095017024094102/tpst-20240808.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-094102

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer